TCGA-77-6844-01A-11R-1949-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.470
- E2F_TARGETS+0.450
- MYC_TARGETS_V2+0.390
- MITOTIC_SPINDLE+0.250
- KRAS_SIGNALING_DN+0.220
- PI3K_AKT_MTOR_SIGNALING+0.180
- MYC_TARGETS_V1+0.130
- WNT_BETA_CATENIN_SIGNALING+0.110
- FATTY_ACID_METABOLISM+0.070
- HEDGEHOG_SIGNALING+0.040
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- ALLOGRAFT_REJECTION-0.410
- TNFA_SIGNALING_VIA_NFKB-0.410
- INFLAMMATORY_RESPONSE-0.400
- COMPLEMENT-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- IL2_STAT5_SIGNALING-0.330
- INTERFERON_ALPHA_RESPONSE-0.330
- IL6_JAK_STAT3_SIGNALING-0.320
- COAGULATION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | dd75267f-824e-4ddc-9056-cdf0f500d39b | — | — | 0.910 |
| 2 | TCGA-56-7730-01A-11R-2125-07 | — | cohortSQ2 | 0.887 |
| 3 | b6af1cfd-5316-4ca0-a346-24892149eb17 | — | — | 0.880 |
| 4 | TCGA-56-A4BX-01A-11R-A24H-07 | — | cohortSQ2 | 0.879 |
| 5 | TCGA-98-A53A-01A-11R-A262-07 | — | cohortSQ1 | 0.878 |
| 6 | TCGA-56-7221-01A-11R-2045-07 | — | cohortSQ2 | 0.876 |
| 7 | SRR6013540 | — | cohortSQ2 | 0.876 |
| 8 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.874 |
| 9 | TCGA-85-8580-01A-31R-2403-07 | — | cohortSQ2 | 0.871 |
| 10 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.030 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |